Avadel Pharma (AVDL) announces favorable ruling in LUMRYZ case
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
Avadel Pharmaceuticals Announces Favorable Ruling in Appeal of Delaware Court Injunction
May 6, 2025 12:30 PM EDT- With this ruling, Avadel can seek and be granted FDA approval for LUMRYZ in Idiopathic Hypersomnia -
- Federal Circuit decision permits new clinical trials and further development of LUMRYZÂ for the treatment of indications beyond narcolepsy -
DUBLIN, Ireland, May 06, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced that the United States Court of Appeals for the Federal Circuit (the Federal Circuit) has ruled in favor of... More
